STERIS Reports Strong Q3 Results, Maintains FY26 Outlook Despite Increased Tariffs

summarizeSummary

STERIS plc announced robust financial results for its fiscal third quarter, with significant revenue and EPS growth, and reaffirmed its full-year guidance despite facing higher tariff costs.

check_boxKey Events

• Strong Q3 Financial Performance

  Total revenue from continuing operations increased 9% to $1.5 billion, with constant currency organic revenue growing 8% for the quarter ended December 31, 2025.

• EPS Growth Exceeds Prior Year

  As reported diluted EPS from continuing operations increased to $1.96, and adjusted diluted EPS rose to $2.53, compared to $1.75 and $2.32 respectively in the prior year's third quarter.

• Robust Segment Growth Across the Board

  All three segments—Healthcare, Applied Sterilization Technologies (AST), and Life Sciences—reported increased revenue and operating income, indicating broad strength.

• Increased Free Cash Flow

  Net cash provided by operations for the first nine months of fiscal 2026 was $1.0 billion, with free cash flow increasing to $737.6 million from $588.1 million in the prior year period.

auto_awesomeAnalysis

STERIS plc demonstrated strong operational execution in its fiscal third quarter, achieving a 9% increase in total revenue and an 8% rise in constant currency organic revenue. This performance translated into healthy EPS growth, both reported and adjusted. All key segments—Healthcare, Applied Sterilization Technologies (AST), and Life Sciences—contributed positively with solid revenue and operating income increases. The company also generated substantial free cash flow. Critically, STERIS maintained its fiscal 2026 outlook, which is a strong signal of confidence, especially considering the increased negative impact from tariffs. This suggests the company is effectively managing headwinds and is on track to meet its financial targets, reinforcing investor confidence in its continued performance.